LENZ Company Profile and Key Details

LENZ has shown mixed momentum, gaining 24.47% over the past week and -49.35% over the past quarter, though year-to-date performance is up 21.12%. Short-term trend indicators are bullishly aligned (SMA20 -2.09%, SMA50 -15.53%, SMA200 -53.47%). The stock’s 14-day RSI is 41.91 (neutral), while the ATR of 1.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.17% below its high and over 17.77% above its low. Average 10-day trading volume of 1.04 million shares is slightly above the 3-month average of 915.78 thousand, indicating heightened recent market interest.

LENZ Therapeutics, Inc. has 28.52 million shares outstanding. The public float is 13.13 million shares, elevated short interest at 24.82% of float. This equals 3.82 million shares. The short ratio is 14.15 days. Institutional investors hold 102.6% of the float. Insiders own 2.73%. Versant Venture Capital VI, L.P. holds 764.13 thousand shares, RA CAPITAL MANAGEMENT, L.P. has 694.76 thousand shares and Schimmelpennink Evert B. has 77.29 thousand shares. Over the past six months, insider transactions show net buying. They sold 5.79 thousand shares across 1 transactions.

LENZ Therapeutics, Inc. generated EPS of -$2.11 over the past year. Five-year average earnings growth is -181.63%. Wall Street analysts project EPS growth of 30.84% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $12.00. The high target offers 747.03% upside. The low target suggests 51.71% downside. The mean target is $42.92. This offers 442.6% upside. LENZ Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 20.0%. The prior quarter beat by 27.47%. Over the last six quarters, Apple has recorded several small beats. These include 9.52% in March 19, 2025.

LENZ Therapeutics, Inc. last paid a dividend of 7.21 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading above this model’s fair value.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) closed at $7.91 USD, losing -$2.08 (-20.82%) from the previous close of $9.99. The stock is currently mid-range between its 52-week high and low $6.83 and $50.40. With a market capitalization of about $248.01 million, LENZ Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.67). Key stats such as the average daily volume over the past year has been around 935.34 thousand shares, trading with heavier-than-usual volume. Headquartered in Solana Beach, CA, LENZ Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Evert Schimmelpennink, the company employs approximately 6 people and listed since March 22, 2024. LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.

LENZ Therapeutics, Inc. trades at a P/E ratio of -2.2, slightly below the S&P 500 average, with a price-to-sales ratio of 11.41 and a price-to-book ratio of 0.97 suggesting the stock is closer to book value. The P/FCF stands at -2.74, also above market averages.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) shares are up 21.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows LENZ Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.2. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $41.82, suggesting 428.7% upside. Our AI forecast model points to short-term strength (8.09% over two weeks), a medium-term fall (-6.83% over three months), and a longer-term loss (-96.33% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that LENZ Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.09%, with price expected at $8.55 by May 26, 2026, within a range of $7.67 to $9.49 3-Month Outlook: Projected fall of -6.83%, reaching $7.37 by August 10, 2026, with a range of $5.22 to $8.39. 1-Year Outlook: Projected loss of -96.33%, with price at $0.29 by May 12, 2027, within a range of $0.00 to $0.00.